Hypofibrinogenemia due to Novel 316 Asp → Tyr Substitution in the Fibrinogen Bβ Chain

Summary

We investigated the molecular basis of hypofibrinogenemia in a woman with a plasma fibrinogen of 1.0 mg/mL. After sequencing the coding region and intronic boundaries of all three fibrinogen genes a single heterozygous GACTAC mutation was identified at codon 316 of the B gene. This AspTyr substitution segregated with the hypofibrinogenemia in the only other affected family member. Examination by SDS-PAGE, isoelectric focussing, reverse phase chromatography and electrospray ionisation (ESI) mass spectrometery, failed to detect expression of the new B chain in purified plasma fibrinogen. The absence of the variant chain was confirmed by ESI tryptic mapping; while the [M + 1 H] and [M + 2 H] ions of the affected peptide (MGPTELLIEMEDWK) were clearly visible at 1,692 and 847 m/z, there were no new signals (1741 or 871 m/z) that would at indicate expression of the variant in plasma. Asp 316 and itschain homologue (Asp 252) are conserved in all known species and this is the first report of a mutation at either of these. The residue appears to be critical in maintaining the structure of the five stranded sheet that forms the dominant structural feature of the D domains.

Keywords

Fibrinogen - hypofibrinogenemia - mutation - mass spectrometery

• References

• 1 Henschen AH, McDonagh J. Fibrinogen, fibrin and factor XIII. In: Blood Coagulation Vol 13. Zwaal RFA, Hemker HC. eds. Amsterdam: Elsevier Science Publishers BV; 1986: 171-241.
• 2 Doolittle RF. The molecular biology of fibrin. In: The Molecular Basis of Blood Diseases. Stamatoyannopoulos G, Nienhuis AW, Majerus PW, Varmus H. eds. Philadelphia: W. B. Saunders Company; 1994: 701-26.
• 3 Marchant RE, Barb MD, Shainoff R, Eppell SJ, Wilson DL, Siedlecki CA. Three dimensional structure of human fibrinogen under aqueous conditions visualised by atomic force microscopy. Thromb Haemost 1997; 77: 1048-51.
• 4 Spraggon G, Everse SJ, Doolittle RF. Crystal structures of fragment D from human fibrinogen and its crosslinked counterpart from fibrin. Nature 1997; 389: 455-62.
• 5 Huang S, Mulvhill ER, Farrell DH, Chung DW, Davies EW. Biosynthesis of human fibrinogen. Subunit interactions and potential intermediates in assembly. J Biol Chem 1993; 268: 8919-26.
• 6 Huang S, Cao Z, Chung DW, Davies EW. The role of βγ and αγ complexes in the assembly of human fibrinogen. J Biol Chem 1996; 271: 27942-7.
• 7 Brennan SO, Hammonds B, George PM. Aberrant hepatic processing causes removal of activation peptide and primary polymerisation site from fibrinogen Canterbury (Aα20 Val→Asp). J Clin Invest 1995; 96: 2854-8.
• 8 Cote HCF, Lord ST, Pratt KP. γ-Chain dysfibrinogenemias: molecular structure-function relationships of naturally occurring mutations in the γ chain of human fibrinogen. Blood 1998; 92: 2195-212.
• 9 Everse SJ, Spraggon G, Doolittle RF. A three-dimensional consideration of variant human fibrinogens. Thromb Haemost 1998; 80: 1-9.
• 10 Fellowes AP, Brennan SO, Ridgway HJ, Heaton DC, George PM. Electro-spray ionization mass spectrometry identification of fibrinogen Banks Peninsula (γ 280Tyr→ Cys): a new variant with defective polymerization. Br J Haematol 1998; 101: 24-31.
• 11 Brennan SO, Fellowes AP, Faed JM, George PM. Hypofibrinogenemia in an individual with two coding (γ82 A → G and Bβ235 P → L) and two non-coding mutations. Blood 2000; 95: 1709-13.
• 12 Terasawa F, Okumura N, Kitano K, Hayashida N, Shimosaka M, Okazaki M, Lord ST. Hypofibrinogenemia associated with a heterozygous missense mutation γ153Cys to Arg (Matsumoto IV): in vitro expression demonstrates defective secretion of the variant fibrinogen. Blood 1999; 94: 4122-31.
• 13 Brennan SO, Wyatt J, Medicina D, Callea F, George PM. Fibrinogen Brescia; Hepatic Endoplasmic Reticulum Storage and Hypofibrinogenemia Because of a γ284 Gly→Arg Mutation. Am J Pathol 2000; 157: 189-96.
• 14 Duga S, Asselta R, Stantagostino E, Zeinali S, Simonic T, Malcovati M, Mannucci PM, Tenchini ML. Missense mutations in the human β fibrinogen gene cause congenital afibrinogenemia by impairing fibrinogen secretion. Blood 2000; 95: 1336-41.
• 15 Koopman J, Haverkate F, Grimbergen J, Egbring R, Lord ST. Fibrinogen Marburg: a homozygous case of dysfibrinogenemia, lacking amino acids Aα 461-610 (Lys₄₆₁ AAA→Stop TAA). Blood 1992; 80: 1972-9.
• 16 Ridgway HJ, Brennan SO, Faed JM, George PM. Fibrinogen Otago: a majorchain truncation associated with severe hypofibrinogenaemia and recurrent miscarriage. Br J Haematol 1997; 98: 632-9.
• 17 Brennan SO. Electrospray ionisation analysis of human fibrinogen. Thromb Haemost 1997; 78: 1055-8.
• 18 Brennan SO, Wyatt JM, Ockelford P, George PM. Defective fibrinogen polymerization associated with a novel γ279Ala → Asp mutation. Br J Haematol 2000; 108: 236-40.
• 19 Ciulla TA, Sklar RM, Hauser SL. A Simple Method for DNA Purification from Peripheral Blood. Anal Biochem 1988; 174: 485-8.